Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 8

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 8
---
,000 shares of our common stock in this offering.(1)                                                                                                                                                                                                                                                                                                |
| Manner of Offering                                 | “At the market” offering that may be made from time to time through or to the Agents, each acting as sales agent or principal. See “Plan of Distribution” on page S-13.                                                                                                                                                                                                                              |
| Use of Proceeds                                    | We currently intend to use the net proceeds from this offering for general corporate purposes, including working capital, research and development, payments for research and development — licenses acquired, sales and marketing activities, general administrative matters, operating expenses and capital expenditures. See “Use of Proceeds” on page S-9 of this prospectus supplement.         |
| Risk Factors                                       | Investing in our common stock involves significant risks. See “Risk Factors” on page S-6 of this prospectus supplement, on page 5 of the accompanying prospectus and under similar headings in other documents incorporated by reference into this prospectus supplement, for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock. |
| Nasdaq Capital Market symbol                       | “DERM”                                                                                                                                                                                                                                                                                                                                                                                               |

| (1) | The number of shares of common stock outstanding is based on an aggregate of 20,309,844 shares of common                   
 stock and 6,000,000 shares of Class A Common Stock outstanding as of August 25, 2025, and excludes 1,817,157 shares of our 
 common stock available as of August 25, 2025 for future grant or issuance pursuant to the Journey Medical Corporation 2015 
 Stock Incentive Plan and 139,036 shares reserved for issuance under the Journey Medical 2023 Employee Stock Purchase Plan. |

<div align='center'>S-5

RISK FACTORS</div>

Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below and under the section titled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, as updated by our subsequent filings, which are incorporated by reference into this prospectus supplement, before deciding whether to purchase any of the securities being registered pursuant to the registration statement of which this prospectus supplement is a part. Each of the risk factors could adversely affect our business, results of operations, financial condition